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Inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6),
are individually considered as important contributors to endothelial dysfunction in obesity
and type 2 diabetes (T2D). However, their interactions in coronary arteriole endothelial dys-
function are uncertain. Therefore, this study aimed to determine the effects of TNF-α and IL-
6 interactions on coronary endothelial dysfunction in experimental T2D.
Methods
The studies used wild type (WT), diabetic mice (db/db), db/db null for TNF (dbTNF-/dbTNF-),
and db/db mice treated with neutralizing antibody to IL-6 (anti-IL-6). Endothelium-dependent
(acetylcholine [ACh], or luminal flow-induced shear stress) and endothelium-independent
(sodium nitroprusside [SNP]) vasodilation of isolated and pressurized coronary arterioles
were determined. Quantitative PCR, Western blot, and immunofluorescence staining were
utilized for mechanistic studies.
Results
Relative to WT, arteriolar dilation to both ACh and flow was attenuated in db/db mice and
dbTNF-/dbTNF-. Treatment of dbTNF-/dbTNF- and db/db mice with anti-IL-6 improved arteriolar
dilation compared to db/db mice. Immunofluorescence staining illustrated localization of IL-
6 within the endothelial cells of coronary arterioles. In db/db mice, mRNA and protein
expression of IL-6 and superoxide (O2-) production were higher, but reduced by anti-IL-6
treatment. Also, in db/db mice, mRNA and protein expression of TNF-α suppressed by the
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anti-IL-6 treatment and the reduced expression of mRNA and protein expression of IL-6 by
the genetic deletion of TNF-α both supported a reciprocal regulation between TNF-α and IL-
6. Superoxide dismutase 2 (SOD2) expression and phosphorylation of eNOS (p-eNOS/
eNOS) were lower in db/db mice coronary arterioles and were restored in db/db+Anti-IL-6
and dbTNF-/dbTNF- mice.
Conclusion
The interactions between TNF-α and IL-6 exacerbate oxidative stress and reduce phosphor-
ylation of eNOS, thereby contributing to coronary endothelial dysfunction in T2D mice.
Introduction
Obesity and type 2 diabetes (T2D) are frequently associated with cardiovascular diseases
(CVD) [1, 2]. Vascular endothelial dysfunction, occurring at an early stage of atherosclerosis,
is an important predictor of impending vascular pathology [3]. Reduced bioavailability of
nitric oxide (NO), a major endothelium-dependent vasodilator, is a direct indicator of vascular
endothelial dysfunction in chronic obesity and T2D [4–6]. In obesity and T2D, excess visceral
fat appears to be a primary contributor to the chronic systemic low-grade inflammation linked
to endothelial dysfunction and vascular inflammation [7]. Consequently, pro-inflammatory
cytokines have emerged as key players in the vascular pathology associated with both obesity
and T2D [7]. Although several inflammatory cytokines have been extensively studied for their
contribution to endothelial dysfunction in obesity and T2D [8–13], it is less certain if some of
the inflammatory cytokines may regulate the expression of others, and how interactive regula-
tion contributes to the progression of vascular disease in T2D.
The pro-inflammatory cytokine TNF-α is a crucial regulator in insulin resistance [10, 14,
15] and endothelial dysfunction in T2D [8–10, 13, 16]. Previously, we reported that in pre-dia-
betic rat and diabetic mouse (db/db) models, TNF-α was responsible for impaired endothe-
lium-dependent vasodilation in the coronary microcirculation [8–10, 17, 18]. Mechanistically,
this occurred via increased production of NADPH-derived superoxide (O2
-) radicals, which
suppressed endothelial nitric oxide synthase (eNOS) signaling pathways and enhanced mono-
cyte/macrophage infiltration into heart and coronary vascular tissues [8–10, 16, 19]. Pro-
inflammatory IL-6, a biomarker of obesity and T2D [14, 20, 21] is a critical contributor to
insulin resistance [22–24], and cardiovascular disease, including myocardial infarction and
atherosclerosis [14, 25, 26]. The depletion of IL-6 signaling protected against angiotensin II-
induced NO-mediated endothelial dysfunction in mouse carotid artery [11]. We previously
reported that IL-6 neutralization restored impairment of endothelium-derived hyperpolariz-
ing factors (EDHF)-mediated coronary endothelial function in a diabetic mouse model (db/
db) [18]. These results provide an evidence that IL-6 plays an important role in endothelial
dysfunction. Despite such a significant contribution of IL-6 and TNF-α to endothelial dysfunc-
tion as described above, a knowledge gap investigating how IL-6 and TNF-α affect each other
in endothelial cell in T2D still exists. Interestingly, same previous study [18] found that IL-6
mRNA and protein expressions were significantly reduced in dbTNF-/dbTNF- mice suggesting
TNF-α could be a mediator of IL-6, but the interactive relationship between TNF-α and IL-6
contributing to the endothelial dysfunction of coronary microcirculation in T2D has not been
clearly established yet.
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Therefore, we hypothesized that IL-6 is a critical contributor to coronary endothelial dys-
function in T2D and that the interaction between IL-6 and TNF-α exacerbates endothelial dys-
function. To test the two hypotheses, we investigated: 1) Whether IL-6 contributes to the
impairment of endothelial function in db/db mice; 2) Whether IL-6 and TNF-α interact to
cause T2D-induced endothelial dysfunction; 3) The localization of IL-6 in vascular cells; and
4) The cellular mechanisms by which IL-6 mediates endothelial dysfunction in coronary
microcirculation in db/db mice.
Materials and methods
Mice
Male mice at 20–24 weeks of age were used. Heterozygote controls (m Leprdb, WT), homozy-
gote type 2 diabetes (Leprdb, db/db), and the breeding pairs of db/db mice null for TNF-α
(dbTNF-/dbTNF-) mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA)
and maintained on a normal control chow diet. The same strain (C57BL/6J) of m Leprdb and
dbTNF-/dbTNF- was used to match the backgrounds of Leprdb. The cross (dbTNF-/dbTNF-) of
Leprdb with TNF knockout was heterozygous for Leprdb and homozygous for TNF knockout
(TNF-/-). Genotyping of dbTNF-/dbTNF- mice was performed to confirm the TNF-/-.
dbTNF-/dbTNF- mice from the second round of breeding of Leprdb and TNF-/- were used in sub-
sequent experiments, and they showed the phenotypes of hyperglycemia and severe obesity,
and the diabetic phenotype consistent with the penetrance of the leptin receptor mutation
[16]. All procedures were approved by the University of Missouri Animal Care and Use
Committee.
Functional assessment of isolated coronary arterioles
At 20–24 weeks of age, the mice were anesthetized with pentobarbital sodium (50 mg/kg)
intraperitoneal injection and sacrificed by isolation of heart. Coronary arterioles were isolated
as previously described [18, 27]. In brief, individual coronary arterioles (40–100 μm diameter
in situ) were dissected from mouse hearts for in vitro studies. Both ends of the vessels were
cannulated with glass micropipettes and secured with nylon suture. Vessels were then pressur-
ized to 60 cmH2O intraluminal pressure using two independent hydrostatic pressure reser-
voirs connected to the inflow and outflow pipettes. The cannulated vessel was bathed in a
physiological salt solution (PSS) containing BSA (1%) at 37˚C. Vessels not holding pressure
were discarded. After development of endothelin-1-induced (0.1 nmol/L to 10 nmol/L) basal
tone, the experimental interventions were performed. Endothelin-1-induced vascular tone was
washed out between experiments.
Coronary arteriolar endothelium-dependent vasodilation was assessed as diameter
responses to either ACh (1 nmol/L to 10 umol/L) or luminal flow (induced by pressure differ-
ences of 4–60 mmH20). Endothelium-independent vasodilation was measured using the NO
donor, sodium nitroprusside (SNP; 1 nmol/L to 10 umol/L). To determine the involvement of
a NO-mediated mechanism in the differences in endothelium-dependent vasodilatation
among WT, db/db, dbTNF-/dbTNF-, and db/db+anti-IL-6 mice, ACh-induced vasodilation was
also performed in the presence of the NOS inhibitor NG-nitro-L-arginine-methyl ester
(L-NAME; 10 umol/L, 20 min). To investigate the role of the O2
- in altered vasoactive
responses, ACh-induced vasodilatory function was examined in the presence of the O2
- scav-
enger TEMPOL (a membrane-permeant O2
- dismutase mimetic; 1 mmol/L, 60 min incuba-
tion). To determine the role of IL-6, incubation of IL-6 (5 ng/ml) was incubated to isolated
coronary arteriole in the vascular bath, and neutralization of IL-6 using anti-mouse IL-6 (0.28
mg/ml/kg, I.P. for 5 days, eBioscience) was performed.
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Immunofluorescence staining
To identify and localize IL-6 protein in coronary arterioles, transverse sections of the mouse
heart were stained using markers of endothelial cells, vascular smooth muscle cells, and macro-
phages. Freshly isolated hearts were embedded and frozen in OCT and sectioned at 5 μm.
Slides were incubated with blocking solution (10% donkey serum in PBS) and permeabilized
(0.1% Triton X-100 in PBS). Primary antibodies to IL-6 (goat polyclonal 15 micro g/ml, AF-
406-NA; R&D), the endothelial cell marker, von Willebrand factor (vWF; rabbit polyclonal,
1:1,000, ab6994; Abcam), smooth muscle α-actin (rabbit polyclonal, 1:800, ab5964; Abcam), or
macrophage marker CD68 (rat monoclonal, 1:1000, ab53444; Abcam) were used for sequential
double immunofluorescence staining. Secondary antibodies were conjugated with the fluoro-
phores FITC or Texas red. Sections were mounted in an anti-fading agent (Slowfade gold with
DAPI; Invitrogen), and then the slides were observed and analyzed with a fluorescence micro-
scope (IX81; Olympus) with a x40 objective (0.90 numerical aperture). For negative controls,
primary antibodies were replaced with goat polyclonal IgG (Abcam), rabbit polyclonal IgG
(GeneTex), and rat monoclonal IgG (Abcam) isotype controls at the same concentration [28].
The specificity of the primary antibody was confirmed as the absence of immunofluorescence
staining signals in the IL-6-/- mice.
Western blot analysis of protein expression
Hearts or coronary arterioles were homogenized in lysis buffer (Cellytic MT Mammalian Tis-
sue/ Lysis/extraction Reagent; Sigma). Protein concentrations were measured using a BCA
Protein Assay Kit (Pierce) and equal amounts of protein (10, 20, or 40 μg) separated by
SDS-PAGE and transferred onto nitrocellulose membranes. Protein expression was detected
using the appropriate primary antibody: TNF-α (1:500; R&D Systems), IL-6 (1:500; Abcam,
Inc.), SOD2 (1:1,000; EMD Chemical), eNOS (1:100; Santa Cruz Biotechnology), p-eNOS
(1:100; Santa Cruz Biotechnology), β-actin (1:2,000; Abcam Inc.), and corresponding second-
ary antibodies (1:1,000~2,000 dilution). Signals were enhanced by chemiluminescence (ECL;
Amersham) and visualized with a Fuji LAS3000 densitometer. The density of protein bands
obtained from the images was analyzed using Multigauge software (Fuji film). The relative
densities were calculated and normalized to those of the corresponding internal reference β-
actin, and then normalized to the corresponding WT control mice, which was set to a value of
1.0.
Quantitative PCR for mRNA expression
Quantitative PCR (qPCR) was used to analyze mRNA expression for IL-6 and TNF-α in
mouse cardiac tissues, using iCycler iQ5 Real-Time PCR Detection System (BioRad). Total
RNA was isolated with RNeasy Fibrious Tissue Mini RNA Isolation Kit (Qiagen), and was
reverse transcribed using Superscript III Reverse Transcript (Life Technologies Inc.). cDNA
was amplified using qPCR Kit with SYBR1 Green (Life Technologies Inc.). Data were quanti-
fied by the 2-ΔΔCT method as reported [29] and presented as fold change in transcripts for IL-6
or TNF-α genes (in db/db, db/db treated with neutralizing antibody to IL-6, and dbTNF-/
dbTNF- mice) normalized to β-actin, and compared to the WT mice (defined as 1.0 fold).
Measurement of superoxide by electron paramagnetic resonance
spectroscopy
Superoxide (O2)
- was quantified from the electron paramagnetic resonance (EPR) spectra of
homogenates of mouse heart tissues. EPR peaks underwent double integration with reference
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to a standard curve generated from horseradish peroxidase-induced production of the anion
from a standard solution of H202, using p-acetamidophenol as the cosubstrate [10, 30]. The
values were then normalized to the mean value of WT mice.
Data analysis
Arteriolar diameter changes to pharmacological agonists were normalized to baseline diame-
ter (pre-drug, 60 cmH2O) and expressed as a percentage. Normalized diameters were aver-
aged at each concentration of agonist used and were shown as mean ± SEM. For statistical
comparison, vasomotor responses under different treatments and molecular studies between
groups were performed using two-way analysis of variance (ANOVA) and one-way
ANOVA, respectively. If a significant difference was obtained by ANOVA, the intergroup




Table 1 shows the characteristics of the WT, db/db, dbTNF-/dbTNF-, and db/db+Anti-IL-6 mice
at 20–24 weeks of age. Body weight and abdominal girth were significantly higher in db/db,
dbTNF-/dbTNF-, and db/db+Anti-IL-6 compared to the WT mice. Non-fasting plasma glucose
concentrations in the db/db, dbTNF-/dbTNF-, and db/db+Anti-IL-6 mice were significantly
higher compared to the WT mice (Table 1). The current study utilized the new sets of animals;
the animal characteristics were similar to our previous findings [18].
Contribution of IL-6 to coronary endothelial function in T2D mice
ACh-induced and flow-mediated endothelium-dependent vasodilation were significantly
impaired in coronary arterioles isolated from the db/db mice in either a concentration or
flow-dependent manner compared to the WT mice. To demonstrate the contribution of IL-6
to the impaired endothelium-dependent vasodilation in diabetic mice, coronary arterioles
from WT mice were exposed to IL-6 (5 ng/ml). IL-6 attenuated endothelium-dependent
vasodilation to the level of db/db, but an IL-6 neutralizing antibody to the db/db mice
restored it (Fig 1A and 1B). To identify specificity for coronary endothelial cell dysfunction,
smooth muscle cell-dependent vasodilatation was examined by cumulative responses to
SNP. SNP-induced endothelium-independent vasodilation was identical across all mice
groups (Fig 1C).
Table 1. Animal characteristics.
WT db/db db/db+Anti-IL-6 dbTNF-/dbTNF-
N 11 13 6 6
Body Weight (g) 28.9±0.4 58.2±2.3* 56.7±2.8* 53.0±5.5*
Abdominal Girth (cm) 8.3±0.2 12.3±0.2* 12.6±0.2* 11.1±0.5*
Glucose (mg/dl) 206±10 434±18* 434±31* 464±23*
Body weight, abdominal girth, and plasma level of glucose were significantly greater in the db/db, db/db mice+Anti-IL-6, and dbTNF-/dbTNF- compared to the
WT mice. Differences in body weight, abdominal girth, and glucose concentration were insignificant in the db/db mice+Anti-IL-6 and dbTNF-/dbTNF-
compared to the db/db mice.
*p<0.05 vs. WT.
https://doi.org/10.1371/journal.pone.0187189.t001
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Interactions between TNF-α and IL-6 contribute to endothelial
dysfunction in T2D mice
To investigate the interactions between TNF-α and IL-6 in coronary endothelial dysfunction
in T2D mice, a db/db mouse model null for TNF-α was used. Significantly improved vasodila-
tory responses to both ACh and intraluminal flow were observed in coronary arterioles from
the dbTNF-/dbTNF- mice compared to the db/db mice (Fig 2A and 2B). As these results
appeared similar to those obtained in the db/db mice treated with anti-IL-6 neutralizing anti-
body, vessels were incubated ex vivo with IL-6. Notably, despite TNF gene knockout, IL-6
caused impaired endothelial function in dbTNF-/dbTNF- vessels to levels observed in the db/db
mice (Fig 2A and 2B). Treatment of the dbTNF-/dbTNF- mice with anti-IL-6 neutralizing anti-
body restored endothelium-dependent vasodilation equivalent to those of the WT mice (Fig
2A and 2B). Endothelium-independent relaxations were similar across all groups (Fig 2C).
Immunofluorescent localization of IL-6 to coronary arteriolar endothelial
cells in T2D
A dual immunostaining approach was used to identify the cellular localization of IL-6. Endo-
thelial cells were identified by positive staining for vWF and vascular smooth muscle cells were
identified by the presence of α-actin. While IL-6 was expressed in endothelial cells of coronary
arterioles in the control mice (Fig 3A–3C), it was more abundant in endothelial cells of the db/
db mice (Fig 3D–3F). IL-6, however, appeared to be absent in vascular smooth muscle cells of
the control (Fig 3G–3J) and db/db mice (Fig 3K–3N). Further, IL-6 was absent in infiltrated
macrophages in the db/db mouse heart tissues (Fig 3O–3Q). Whether IL-6 is expressed by
other immune cells, including T-cell and dendritic cells [31] that have also been implicated in
inflammation, remains to be determined.
Fig 1. Contribution of IL-6 to endothelial dysfunction in T2D. (A) Isolated coronary arterioles from the WT (n = 11) and db/db mice
(n = 13) dilated in a concentration-dependent manner to ACh. ACh-induced endothelium-dependent vasodilation was significantly reduced
in the db/db mice compared to the WT mice. Incubation of IL-6 in coronary arterioles from the WT (n = 7) mice attenuated ACh-induced
vasodilation. However, neutralizing antibody to IL-6 (n = 6) restored ACh-induced vasodilation of arterioles from the db/db mice. (B) Flow-
induced vasodilation of coronary arterioles was impaired in the db/db mice (n = 11) compared to the WT mice (n = 10), but was enhanced by
treatment with a neutralizing antibody to IL-6 (n = 6). Further, ex vivo exposure of WT coronary arterioles to IL-6 decreased flow-mediated
vasodilation. (C) Vasodilation to the endothelium-independent vasodilator was not significantly different in any of the 4 groups of mice
(n = 6~13). Data are shown as mean ± SEM. * p <.05 vs. db/db; # p <.05 vs. db/db+Anti-IL-6.
https://doi.org/10.1371/journal.pone.0187189.g001
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Interactive inhibitory effects between IL-6 and TNF-α in T2D
To obtain mechanistic insights, the effects of anti-IL-6 antibody treatment or TNF-α gene
knockout on cytokine mRNA expression and protein levels were determined. Both IL-6 and
TNF-α mRNA and protein levels were significantly greater in db/db mouse hearts compared
to the WT mice (Fig 4A–4D). The reduced IL-6 mRNA and protein expression in the dbTNF-/
dbTNF- mice (Fig 4A and 4B) were reproduced in the current study using the new sets of ani-
mal groups from our previous study [18]. The results supported the mediation of coronary
endothelial dysfunction in the db/db mice by the increased production of IL-6. In contrast, the
dbTNF-/dbTNF- and db/db+Anti-IL-6 treated mice demonstrated significantly attenuated
mRNA and protein expression levels of IL-6 and TNF-α, respectively. Thus, treatment of anti-
IL-6 and depletion of TNF-α exerted inhibitory effects on IL-6 protein and mRNA expression.
Taken together, the results indicated that anti-IL-6 neutralization and TNF-α deficiency had
the interactive inhibitory effects on mutual protein and mRNA expression.
Effect of ROS on coronary endothelial dysfunction in T2D
It has been reported that increased ROS production directly contributes to vascular dysfunc-
tion by inhibiting eNOS signaling and decreasing NO availability [4, 5, 32]. To investigate the
mechanism(s) involved in impaired vasodilation in the coronary arteriole of T2D mice, super-
oxide (O2
-) production and a cytosolic antioxidant enzyme, SOD2, protein levels were exam-
ined. Markedly increased O2
- production was observed in diabetic mouse hearts, but was
prevented by treatment with anti-IL-6 antibody or by TNF-α gene-deletion (Fig 5A). Dimin-
ished cardiac protein levels of SOD2 in the db/db mice compared to the WT mice were also
observed. SOD2 protein levels were higher in the anti-IL-6 treated db/db mice or null for
TNF-α compared to the db/db mice, which were similar to the levels in WT mouse hearts (Fig
5B). To provide functional evidence for diabetes-induced O2
- production causing vascular
Fig 2. Interaction between TNF-α and IL-6 in endothelial dysfunction in T2D. (A) ACh-induced vasodilation in db/db mice null for TNF
(dbTNF-/dbTNF-, n = 6) mice was similar to that in the WT mice and significantly higher than in the db/db mice. IL-6 attenuated ACh-induced
vasodilation in dbTNF-/dbTNF- mice (n = 6) to the levels observed in the db/db mice. (B) Flow-induced vasodilation in the db/db mice (n = 13)
was impaired while it was preserved in dbTNF-/dbTNF- mice (n = 6) which was similar to the WT mice (n = 11). Exogenous IL-6 decreased
flow-mediated vasodilation of dbTNF-/dbTNF- mice coronary arteriole (n = 6). (C) Endothelium-independent vasodilator responses to SNP
were similar across all groups (n = 6~13). Data are shown as mean ± SEM. * p <.05 vs. db/db; † p <.05 vs. dbTNF-/dbTNF-.
https://doi.org/10.1371/journal.pone.0187189.g002
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Fig 3. IL-6 localized to endothelial cells of coronary arterioles. Dual fluorescence combining IL-6 with
markers for endothelial cells [von Willebrand factor (vWF)], vascular smooth muscle cells (α-actin) and
macrophages (CD68). (A, B, and C) Dual labeling of IL-6 (red) and vWF (green) in control mouse heart
tissues. (D, E, and F) Dual labeling of IL-6 (red) and vWF (green) in db/db mouse heart tissues. Arrows in C
and F show the colocalization of IL-6 and endothelial cells (yellow) in the control and db/db mice. (G, H, and I)
Dual labeling of IL-6 (red) and α-actin (green) in control mouse heart tissues. (K, L, and M) Dual labeling of IL-
6 (red) and α-actin (green) in heart tissues of db/db. Arrows in I and M show the α-actin staining with absence
of IL-6 staining in the control and db/db mice. Inserts in I (J) and in M (N) show the higher magnification
indicated by arrows in I and M. O, P, and Q, dual labeling of IL-6 (red) and marker of macrophage (green) in
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dysfunction, isolated coronary arterioles were incubated with the O2
- scavenger, TEMPOL.
Eliminating O2
- significantly restored endothelium-dependent relaxation in coronary arteri-
oles from the diabetic mice at the levels observed in the anti-IL-6 treated diabetic mice or
dbTNF-/dbTNF (Fig 5C). The results indicated that the elevated ROS production levels caused
by the reduced SOD2 mediated coronary endothelial dysfunction in diabetes. Further,
db/db mouse heart tissues. Arrows in Q show the specific CD68 staining with absence of IL-6 staining. (R and
S) Negative control: arrows show the absence of staining in vessels with control IgG and without primary
antibodies. (T) Staining of nuclei with DAPI (blue) in heart tissues of the db/db mice. The immunostaining
results suggest that in the hearts of type 2 diabetic mice, IL-6 is mainly localized in endothelial cells, but not in
vascular smooth muscle cells and macrophages. Magnification×40. Data shown are representative of 4
separate experiments.
https://doi.org/10.1371/journal.pone.0187189.g003
Fig 4. Interactive inhibition between IL-6 and TNF-α expression in diabetic endothelial cells. (A) mRNA expression of IL-6
was higher (3.6-fold) in the db/db mice compared to the WT mice, and significantly attenuated in the db/db mice treated with anti-
IL-6 and in diabetic mice null for TNF-α (dbTNF-/dbTNF-). (B) Protein levels of IL-6 were higher in the db/db mice compared to the
WT mice, but lower in the anti-IL-6 antibody-treated and dbTNF-/dbTNF- mice. (C) TNF-αmRNA expression was approximately
8-fold higher in the db/db mice compared to the WT mice, but significantly lower after treatment with the IL-6 neutralizing antibody.
(D) TNF-α protein levels were significantly higher in the db/db mice compared to the WT mice, but decreased in the diabetic mice
receiving neutralizing antibody to IL-6 (n = 6~11). Data are shown as mean ± SEM. * p <.05 vs. WT; # p <.05 vs. db/db.
https://doi.org/10.1371/journal.pone.0187189.g004
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elimination of either IL-6 or TNF-α restored the impaired redox balance between the levels of
ROS and the antioxidant directly responsible for endothelial dysfunction.
Role of eNOS in endothelial dysfunction in coronary arteriole of T2D
Figs 1 and 2 demonstrated that removal of either IL-6 or TNF-α restored endothelial dysfunc-
tion in db/db mice coronary arterioles. Since eNOS-mediated NO production has a major role
in endothelium-dependent vasodilation, we also investigated whether eNOS was responsible
for restored endothelial function in coronary arterioles from anti-IL-6 antibody-treated db/db
and dbTNF-/dbTNF- mouse hearts. We found that incubation with the eNOS inhibitor,
L-NAME, significantly decreased the improved endothelium-dependent vasorelaxation in the
Fig 5. Effect of ROS on coronary endothelial dysfunction in T2D. (A) O2- production was significantly higher in db/db mouse hearts
compared to the WT mice, but attenuated in the anti-IL-6 treated db/db or null for TNF-α (dbTNF-/dbTNF-). (n = 6~11) (B) Protein levels of
SOD2 were reduced in db/db mouse hearts, but restored to the level of the WT mice in both the anti-IL-6 db/db treated db/db mice and
db/db mice null for TNF-α. (n = 6~11) (C) Incubation of TEMPOL restored endothelial function in db/db (n = 8) to the levels observed in
dbTNF-/dbTNF- or WT mice. Data are shown as mean ± SEM. * p <.05 vs. WT, # p <.05 vs. db/db.
https://doi.org/10.1371/journal.pone.0187189.g005
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db/db mice neutralized with anti-IL-6 and null for TNF-α (Fig 6A). The data are supported by
the decreased protein levels of phosphorylated eNOS (p-eNOS) and p-eNOS/eNOS ratio in
the db/db mice and the increased ratios in the anti-IL-6 antibody-treated db/db and dbTNF-/
dbTNF- (Fig 6B and 6D) mice. Taken together, the findings indicated that the presence of IL-6
or TNF-α in diabetic mice was associated with the reduced phosphorylation of eNOS-medi-
ated endothelial dysfunction.
Discussion
The results of this study provide evidence that either IL-6 inhibition or TNF deficiency has an
interactive down-regulatory action on the other in type 2 diabetic coronary arterioles and it
Fig 6. Role of eNOS in endothelial dysfunction in diabetic mouse coronary arterioles. (A) Treatment with the eNOS inhibitor,
L-NAME, attenuated the improved endothelial function by inhibition of either TNF-α (n = 6) or IL-6 in the db/db mice (n = 10), but not in
the db/db mice (n = 8). (B) Levels of p-eNOS protein were significantly decreased in db/db mouse hearts, but were restored in the anti-
IL-6 treated db/db mice or db/db mice null for TNF-α null for at levels similar to the WT mice. (C) No differences in total eNOS protein
levels were observed between groups (n = 6~11). (D) The ratio of p-eNOS to eNOS protein expression was reduced in db/db mouse
hearts compared to the WT mice, while the ratios in the anti-IL-6 treated db/db mice and null for TNF-αwere significantly higher than
db/db (n = 6~11). Data are shown as mean ± SEM. * p <.05 vs. WT; # p <.05 vs. db/db; ‡ p <.05 vs. WT+L-NAME.
https://doi.org/10.1371/journal.pone.0187189.g006
PLOS ONE | https://doi.org/10.1371/journal.pone.0187189 November 2, 2017 11 / 17
contributes to the endothelial dysfunction. The major findings of this study are as follows: 1)
ACh- and flow-induced endothelium-dependent vasodilation was impaired in coronary arteri-
oles of diabetic mice, and was mediated by IL-6 and TNF-α signaling; 2) Interactions between
IL-6 and TNF-α determined the mRNA and protein expression levels for both IL-6 and TNF-
α contributing to coronary endothelial dysfunction in T2D; and 3) Coronary endothelial dys-
function in T2D was regulated by IL-6 through increased production of superoxide and subse-
quent reduction in p-eNOS. Our findings may provide novel insight for the prevention and
management of coronary artery disease associated with metabolic syndromes including obe-
sity and type 2 diabetes.
Role of IL-6 in coronary arteriolar endothelial dysfunction of T2D
Available evidence indicates that endothelial dysfunction is often closely related to a state of
inflammation. Previously, we reported that TNF-α has a crucial role in endothelial dysfunction
in T2D by activating the glycation end (AGE) product/receptor of AGE (RAGE) and the
nuclear factor-kB (NF-kB) signaling pathway [9, 16, 33]. Similar to TNF-α, IL-6 has a role in
the development of T2D and its complications [34, 35]. Increased serum levels of IL-6 repre-
sent an inflammatory biomarker and a risk factor of developing T2D [21, 34]. Consistent with
these studies, Klover et al. reported that chronic IL-6 treatment to the mice directly impaired
hepatic insulin sensitivity and that IL-6 neutralization in diet-induced obese mice improved
hepatic insulin responsiveness, indicating a direct role for IL-6 in insulin resistance [22, 24].
Moreover, some studies have reported a critical role of IL-6 in vascular dysfunction; Wass-
mann et al. [12] observed that exogenous IL-6 treatment to wild type mice caused endothelial
dysfunction in aorta through upregulation of angiotensin II type 1 receptor, while Schrader
et al. [11] reported that IL-6 deficiency protected against angiotensin II-induced endothelial
dysfunction in carotid arteries. Additionally, our group has provided the evidence that IL-6 is
a key contributor to EDHF-mediated coronary endothelial dysfunction in T2D [18]. Despite
its importance, a direct role and underlying mechanism of IL-6 in endothelial dysfunction in
the coronary microcirculation of T2D have not been fully elucidated. To our knowledge the
current study is the first report highlighting that IL-6 directly contributes to the coronary arte-
riolar endothelial dysfunction in T2D mice through enhanced oxidative stress and reduced
phosphorylation of eNOS.
Our data, which demonstrate that impaired endothelium-dependent vasodilation in T2D
mouse coronary arterioles was restored using IL-6 neutralization strategy (Fig 1A and 1B),
provides direct evidence of the key role played by IL-6 in diabetes-induced impairment of
ACh- and the physiologically relevant, flow-mediated vasodilation. We found that T2D-
induced endothelial dysfunction is mediated by an impaired NO-mediated signaling pathway
(Fig 6A). Previous studies, which found that exogenous IL-6 impaired endothelium-dependent
vasodilator responses to ACh through blunted NO cyclic GMP signaling [36], and that IL-6
suppressed the insulin signaling pathway promoting NO production in human umbilical vein
endothelial cells [23], align with our study. The results of our molecular data, which show
reduced p-eNOS protein expression in the db/db mice compared to the WT mice (Fig 6B and
6D), also provide strong evidence to support the vasodilatory dysfunction in db/db mediated
by a reduction of the eNOS activation responsible for NO production. This finding, in part,
corresponds with previous study that incubation (10 ng/ml) of IL-6 to human aortic endothe-
lial cells attenuated eNOS expression [37].
Finally, our immunofluorescence data showing higher expression of IL-6 protein in coro-
nary endothelium compared to the WT mice (Fig 3A–3F) support our conclusion that IL-
6-mediated endothelial dysfunction is induced by attenuated NO signaling pathways in
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endothelial cells. Its higher expression in the endothelial cell appears to have a direct impact
on the impaired endothelium-dependent vasodilation (Fig 1A and 1B), but not on the endo-
thelium-independent vasodilation (Figs 1C and 2C), i.e., we mainly observed IL-6 expressed in
the endothelium, but not in the vascular smooth muscle cells (Fig 3G–3N).
Interactions between TNF-α and IL-6
Pro-inflammatory cytokines, such as TNF-α and IL-6, are implicated in vascular pathophysiol-
ogy. We previously determined the role of TNF-α in endothelium-dependent vascular dys-
function in T2D mouse coronary vessels [16], but the interactive relationship between TNF-α
and IL-6 in vascular pathology has not been clearly identified. Turner et al. [38] reported that
IL-6 mRNA expression was stimulated through TNF-α receptor I and the p38 mitogen-acti-
vated protein kinase, PI3K/Akt, and NF-kB pathway. In a previous study, we suggested that
TNF-α could be an up-regulator of IL-6 at the physiological and molecular levels, i.e., restored
EDHF-mediated endothelial function in the dbTNF-/dbTNF- mice was attenuated in response to
IL-6 incubation and expression of mRNA, and protein IL-6 was reduced in the dbTNF-/dbTNF-
mice [18]. Our current study reproduced these findings by utilizing new sets of animal groups
(Fig 4A and 4B). In contrast, other research has proposed IL-6 as an upstream mediator of
TNF-α expression in vivo and in vitro [39–42]. For example, Santo et al. (23) found that injec-
tion of LPS into IL-6-deficient mice had greatly higher plasma concentrations of TNF com-
pared to wild type mice, while rhIL-6 treatment of macrophages inhibited TNF production.
Schindler et al. [42] found that IL-6 treatment to human peripheral blood mononuclear cells
suppressed TNF expression at the mRNA level.
The current study found that exposure of vessels from the dbTNF-/dbTNF- mice to exogenous
IL-6, reduced endothelium-dependent vasodilation in response to ACh and flow (Fig 2A and
2B). The data suggest that IL-6 has a significant role in coronary arteriolar endothelial dysfunc-
tion in the absence of TNF-α signals. This suggestion agrees with previous studies which
showed that IL-6 treatment to wild type mice impaired endothelium-dependent vasodilation
[12]. Notably, our molecular/cellular results (Fig 4C and 4D) showed that the inhibition of IL-
6 by exogenous IL-6 neutralization suppressed mRNA and protein expressions of TNF-α in
the dbTNF-/dbTNF- indicating IL-6 can in fact regulate the TNF-α signaling in diabetic mice
heart. Our previous study [18] reported the attenuated expression of IL-6 mRNA and protein
and it was reproduced by the current study (Fig 4A and 4B), thus suggesting a possible interac-
tion between IL-6 and TNF-α. The current follow-up study shows that the inhibition of each
inflammatory cytokine, TNF-α and IL-6, has an effect on one another, in particular reciprocal
down-regulatory action (Fig 4A–4D). It implicates that IL-6 and TNF-α are interactive each
other to determine the endothelial dysfunction in type 2 diabetic coronary arterioles, but a fur-
ther study is needed to confirm its direct relationship. It appears to be the first study to find
that a reciprocal inhibitory regulation between TNF-α and IL-6 is responsible for endothelial
dysfunction in T2D. Based on our novel findings of the possible interactive influence between
TNF-α and IL-6, we believe that an anti-inflammatory strategy blocking IL-6 and/or TNF-α
may effectively prevent T2D-mediated endothelial dysfunction in coronary microcirculation.
Inflammation-mediated oxidative stress impairs coronary endothelial
vasodilation in T2D
In concert with hyperglycemia, the inflammatory milieu producing TNF-α is considered a sig-
nificant contributor to the CVD in T2D mainly through the enhanced oxidative stress. Thus,
increased superoxide (O2
-) production via the NAD(P)H oxidase is considered a major con-
tributor to the mechanisms underlying impaired endothelium-dependent vasodilation in
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diabetes [16, 43, 44]. Our findings are consistent with the higher glucose levels (Table 1),
increased TNF-α expression (Fig 4C and 4D), and enhanced superoxide production (Fig 5A)
observed in the db/db mice compared to the control mice. O2
- is known to quickly react with
NO, and leads to the formation of ONOO- (peroxinitrite), which in turn is responsible for
reducing NO biological activity and decreasing vasodilation [45, 46]. Despite many
approaches, such as TNF-α in coronary arterioles and IL-6 in aortic and carotid arteries [9, 11,
12, 16], previous studies have not conclusively identified the role of IL-6 in oxidative stress-
mediated coronary endothelial dysfunction in T2D.
Our data demonstrate that the diabetic condition leads to enhanced expression of IL-6 (Fig
4A and 4B) and increased generation of O2
- (Fig 5A). However, neutralization of anti-IL-6 in
db/db mice showed reduced O2
- production in cardiac tissue (Fig 5A). Previous studies have
shown direct effects of IL-6 on vascular oxidative stress. For example, Wassmann et al. [12]
found that IL-6 was involved in upregulation of oxidative stress and impairment of endothe-
lium-dependent vasodilation in vitro and in vivo, and Schrader et al. [11] reported that IL-
6-deficient mice were resistant to angiotensin II-induced endothelial dysfunction in carotid
arteries, and that vascular O2
- level and eNOS expression were preserved by angiotensin II in
IL-6-deficient mice. These findings indicate the importance of IL-6 in oxidative stress-associ-
ated endothelial dysfunction in vasculature. A cytosolic antioxidant enzyme SOD2-mediated
elimination of reactive oxygen species is a critical mechanism in the survival of aerobic organ-
isms and prevention of pathological conditions [47]. Our current study also found that neu-
tralizing IL-6 in the diabetic mice restored the expression of SOD2 protein to the levels
observed in the WT mice (Fig 5B), suggesting that IL-6 is a pivotal mediator in regulating O2
-
contents. Our findings show that direct exposure of TEMPOL, an O2
- scavenger, to vessels
from diabetic mice reverses endothelial dysfunction, which is similar to the levels observed in
the db/db+anti-IL-6 mice (Fig 5C). This result confirms that IL-6-mediated O2
- production is
a primary mechanism for endothelial dysfunction in T2D coronary arterioles. The present
studies, therefore, strongly suggests that IL-6 is an important contributor of T2D-mediated
endothelial dysfunction, especially through elevated O2
- production and attenuated SOD2 pro-
tein expression.
Conclusion
The interaction of TNF-α and IL-6 appears to have a pivotal role in T2D-induced endothelial
dysfunction in coronary microcirculation. The effect of this interaction is mediated through
enhanced oxidative stress and reduced phosphorylation of eNOS. We conclude that antagoniz-
ing TNF-α and IL-6 is an effective therapeutic approach to ameliorate T2D-associated vascular
diseases.
Author Contributions
Conceptualization: Jonghae Lee, Cuihua Zhang, Yoonjung Park.
Data curation: Jonghae Lee, Sewon Lee, Hanrui Zhang, Yoonjung Park.
Formal analysis: Jonghae Lee, Cuihua Zhang, Yoonjung Park.
Funding acquisition: Michael A. Hill, Cuihua Zhang.
Investigation: Jonghae Lee, Cuihua Zhang, Yoonjung Park.
Methodology: Jonghae Lee, Sewon Lee, Hanrui Zhang, Yoonjung Park.
Project administration: Yoonjung Park.
PLOS ONE | https://doi.org/10.1371/journal.pone.0187189 November 2, 2017 14 / 17
Supervision: Michael A. Hill, Cuihua Zhang, Yoonjung Park.
Validation: Jonghae Lee, Cuihua Zhang, Yoonjung Park.
Visualization: Jonghae Lee.
Writing – original draft: Jonghae Lee, Yoonjung Park.
Writing – review & editing: Jonghae Lee, Sewon Lee, Hanrui Zhang, Michael A. Hill, Cuihua
Zhang, Yoonjung Park.
References
1. Pencina MJ, D’Agostino RB Sr., Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of car-
diovascular disease: the framingham heart study. Circulation. 2009; 119(24):3078–84. Epub 2009/06/
10. https://doi.org/10.1161/CIRCULATIONAHA.108.816694 PMID: 19506114.
2. Meigs JB. Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to
prevention: the Kelly West award lecture 2009. Diabetes care. 2010; 33(8):1865–71. Epub 2010/07/30.
https://doi.org/10.2337/dc10-0641 PMID: 20668155.
3. Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circulation jour-
nal: official journal of the Japanese Circulation Society. 2009; 73(4):595–601. Epub 2009/02/20. PMID:
19225203.
4. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Cir-
culation research. 2000; 87(10):840–4. Epub 2000/11/14. PMID: 11073878.
5. Gamez-Mendez AM, Vargas-Robles H, Rios A, Escalante B. Oxidative Stress-Dependent Coronary
Endothelial Dysfunction in Obese Mice. PloS one. 2015; 10(9):e0138609. Epub 2015/09/19. https://doi.
org/10.1371/journal.pone.0138609 PMID: 26381906.
6. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative
stress in obesity and its impact on metabolic syndrome. The Journal of clinical investigation. 2004; 114
(12):1752–61. Epub 2004/12/16. https://doi.org/10.1172/JCI21625 PMID: 15599400.
7. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart dis-
ease. Obesity research. 2003; 11(11):1278–89. Epub 2003/11/25. https://doi.org/10.1038/oby.2003.
174 PMID: 14627747.
8. Yang J, Park Y, Zhang H, Gao X, Wilson E, Zimmer W, et al. Role of MCP-1 in tumor necrosis factor-
alpha-induced endothelial dysfunction in type 2 diabetic mice. American journal of physiology Heart and
circulatory physiology. 2009; 297(4):H1208–16. Epub 2009/08/12. https://doi.org/10.1152/ajpheart.
00396.2009 PMID: 19666844.
9. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-alpha
induces endothelial dysfunction in the prediabetic metabolic syndrome. Circulation research. 2006; 99
(1):69–77. Epub 2006/06/03. https://doi.org/10.1161/01.RES.0000229685.37402.80 PMID: 16741160.
10. Yang J, Park Y, Zhang H, Xu X, Laine GA, Dellsperger KC, et al. Feed-forward signaling of TNF-alpha
and NF-kappaB via IKK-beta pathway contributes to insulin resistance and coronary arteriolar dysfunc-
tion in type 2 diabetic mice. American journal of physiology Heart and circulatory physiology. 2009; 296
(6):H1850–8. Epub 2009/04/14. https://doi.org/10.1152/ajpheart.01199.2008 PMID: 19363130.
11. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against
angiotensin II induced endothelial dysfunction and hypertrophy. Arteriosclerosis, thrombosis, and vas-
cular biology. 2007; 27(12):2576–81. Epub 2007/10/27. https://doi.org/10.1161/ATVBAHA.107.153080
PMID: 17962626.
12. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, et al. Interleukin-6 induces oxida-
tive stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circula-
tion research. 2004; 94(4):534–41. Epub 2003/12/31. https://doi.org/10.1161/01.RES.0000115557.
25127.8D PMID: 14699015.
13. Donato AJ, Henson GD, Morgan RG, Enz RA, Walker AE, Lesniewski LA. TNF-alpha impairs endothe-
lial function in adipose tissue resistance arteries of mice with diet-induced obesity. American journal of
physiology Heart and circulatory physiology. 2012; 303(6):H672–9. Epub 2012/07/24. https://doi.org/
10.1152/ajpheart.00271.2012 PMID: 22821989.
14. Hossain M, Faruque MO, Kabir G, Hassan N, Sikdar D, Nahar Q, et al. Association of serum TNF-α and
IL-6 with insulin secretion and insulin resistance in IFG and IGT subjects in a Bangladeshi population.
International Journal of Diabetes Mellitus. 2010; 2(3):165–8.
PLOS ONE | https://doi.org/10.1371/journal.pone.0187189 November 2, 2017 15 / 17
15. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in
endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;
148(7):3356–63. Epub 2007/04/21. https://doi.org/10.1210/en.2006-1441 PMID: 17446186.
16. Gao X, Belmadani S, Picchi A, Xu X, Potter BJ, Tewari-Singh N, et al. Tumor necrosis factor-alpha
induces endothelial dysfunction in Lepr(db) mice. Circulation. 2007; 115(2):245–54. Epub 2007/01/04.
https://doi.org/10.1161/CIRCULATIONAHA.106.650671 PMID: 17200442.
17. Park Y, Yang J, Zhang H, Chen X, Zhang C. Effect of PAR2 in regulating TNF-alpha and NAD(P)H oxi-
dase in coronary arterioles in type 2 diabetic mice. Basic Res Cardiol. 2011; 106(1):111–23. https://doi.
org/10.1007/s00395-010-0129-9 PMID: 20972877.
18. Park Y, Capobianco S, Gao X, Falck JR, Dellsperger KC, Zhang C. Role of EDHF in type 2 diabetes-
induced endothelial dysfunction. American journal of physiology Heart and circulatory physiology. 2008;
295(5):H1982–8. Epub 2008/09/16. https://doi.org/10.1152/ajpheart.01261.2007 PMID: 18790831.
19. Gao X, Zhang H, Belmadani S, Wu J, Xu X, Elford H, et al. Role of TNF-alpha-induced reactive oxygen
species in endothelial dysfunction during reperfusion injury. American journal of physiology Heart and
circulatory physiology. 2008; 295(6):H2242–9. Epub 2008/10/14. https://doi.org/10.1152/ajpheart.
00587.2008 PMID: 18849334.
20. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and
diabetes. Trends in immunology. 2004; 25(1):4–7. Epub 2003/12/31. PMID: 14698276.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of
developing type 2 diabetes mellitus. Jama. 2001; 286(3):327–34. Epub 2001/07/24. PMID: 11466099.
22. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action
in obesity. Endocrinology. 2005; 146(8):3417–27. Epub 2005/04/23. https://doi.org/10.1210/en.2004-
1468 PMID: 15845623.
23. Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, et al. Interleukin-6 impairs the
insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells.
Molecular and cellular biology. 2007; 27(6):2372–83. Epub 2007/01/24. https://doi.org/10.1128/MCB.
01340-06 PMID: 17242212.
24. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic
insulin resistance in mice. Diabetes. 2003; 52(11):2784–9. Epub 2003/10/28. PMID: 14578297.
25. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arteriosclero-
sis, thrombosis, and vascular biology. 2007; 27(1):15–26. Epub 2006/11/04. https://doi.org/10.1161/01.
ATV.0000251503.35795.4f PMID: 17082488.
26. Bennet AM, Prince JA, Fei GZ, Lyrenas L, Huang Y, Wiman B, et al. Interleukin-6 serum levels and
genotypes influence the risk for myocardial infarction. Atherosclerosis. 2003; 171(2):359–67. Epub
2003/12/04. PMID: 14644408.
27. Park Y, Booth FW, Lee S, Laye MJ, Zhang C. Physical activity opposes coronary vascular dysfunction
induced during high fat feeding in mice. The Journal of physiology. 2012; 590(17):4255–68. Epub 2012/
06/08. https://doi.org/10.1113/jphysiol.2012.234856 PMID: 22674721.
28. Chen X, Zhang H, Hill MA, Zhang C, Park Y. Regulation of Coronary Endothelial Function by Interac-
tions between TNF-alpha, LOX-1 and Adiponectin in Apolipoprotein E Knockout Mice. Journal of vascu-
lar research. 2015; 52(6):372–82. Epub 2016/04/07. https://doi.org/10.1159/000443887 PMID:
27050429.
29. Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2^(-delta delta CT) method for quantitative real-
time polymerase chain reaction data analysis. Biostatistics, bioinformatics and biomathematics. 2013; 3
(3):71–85. Epub 2013/08/01. PMID: 25558171.
30. Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM, et al. TNF-alpha contributes to endothelial
dysfunction by upregulating arginase in ischemia/reperfusion injury. Arteriosclerosis, thrombosis, and
vascular biology. 2007; 27(6):1269–75. Epub 2007/04/07. https://doi.org/10.1161/ATVBAHA.107.
142521 PMID: 17413034.
31. Heink S, Yogev N, Garbers C, Herwerth M, Aly L, Gasperi C, et al. Trans-presentation of IL-6 by den-
dritic cells is required for the priming of pathogenic TH17 cells. Nature immunology. 2017; 18(1):74–85.
Epub 2016/11/29. https://doi.org/10.1038/ni.3632 PMID: 27893700.
32. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, Al-Mulla F. Nitric oxide dynamics and endothe-
lial dysfunction in type II model of genetic diabetes. European journal of pharmacology. 2005; 511
(1):53–64. Epub 2005/03/22. https://doi.org/10.1016/j.ejphar.2005.01.014 PMID: 15777779.
33. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic research in cardiology.
2008; 103(5):398–406. Epub 2008/07/05. https://doi.org/10.1007/s00395-008-0733-0 PMID:
18600364.
PLOS ONE | https://doi.org/10.1371/journal.pone.0187189 November 2, 2017 16 / 17
34. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic
inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.
Diabetes. 2003; 52(7):1799–805. Epub 2003/06/28. PMID: 12829649.
35. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabe-
tes in women. Diabetes. 2004; 53(3):693–700. Epub 2004/02/28. PMID: 14988254.
36. Orshal JM, Khalil RA. Interleukin-6 impairs endothelium-dependent NO-cGMP-mediated relaxation and
enhances contraction in systemic vessels of pregnant rats. American journal of physiology Regulatory,
integrative and comparative physiology. 2004; 286(6):R1013–23. Epub 2004/05/15. https://doi.org/10.
1152/ajpregu.00729.2003 PMID: 15142856.
37. Saura M, Zaragoza C, Bao C, Herranz B, Rodriguez-Puyol M, Lowenstein CJ. Stat3 mediates interleu-
kin-6 [correction of interelukin-6] inhibition of human endothelial nitric-oxide synthase expression. The
Journal of biological chemistry. 2006; 281(40):30057–62. Epub 2006/08/05.
38. Turner NA, Mughal RS, Warburton P, O’Regan DJ, Ball SG, Porter KE. Mechanism of TNFalpha-
induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thia-
zolidinediones. Cardiovascular research. 2007; 76(1):81–90. Epub 2007/07/07. https://doi.org/10.1016/
j.cardiores.2007.06.003 PMID: 17612514.
39. Di Santo E, Alonzi T, Poli V, Fattori E, Toniatti C, Sironi M, et al. Differential effects of IL-6 on systemic
and central production of TNF: a study with IL-6-deficient mice. Cytokine. 1997; 9(5):300–6. Epub 1997/
05/01. https://doi.org/10.1006/cyto.1996.0169 PMID: 9195128.
40. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response
in interleukin 6-deficient mice. The Journal of experimental medicine. 1994; 180(4):1243–50. Epub
1994/10/01. PMID: 7931061.
41. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in
cultured human monocytes, U937 cells, and in mice. Journal of immunology (Baltimore, Md: 1950).
1989; 143(11):3517–23. Epub 1989/12/01. PMID: 2584704.
42. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in
the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononu-
clear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990; 75(1):40–7. Epub 1990/01/01. PMID: 2294996.
43. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: molecular
mechanisms and clinical implications. Reviews in endocrine & metabolic disorders. 2010; 11(1):61–74.
Epub 2010/02/27. https://doi.org/10.1007/s11154-010-9134-4 PMID: 20186491.
44. San Martin A, Du P, Dikalova A, Lassegue B, Aleman M, Gongora MC, et al. Reactive oxygen species-
selective regulation of aortic inflammatory gene expression in Type 2 diabetes. American journal of
physiology Heart and circulatory physiology. 2007; 292(5):H2073–82. Epub 2007/01/24. https://doi.org/
10.1152/ajpheart.00943.2006 PMID: 17237245.
45. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly.
The American journal of physiology. 1996; 271(5 Pt 1):C1424–37. Epub 1996/11/01. PMID: 8944624.
46. Kozak AJ, Liu F, Funovics P, Jacoby A, Kubant R, Malinski T. Role of peroxynitrite in the process of vas-
cular tone regulation by nitric oxide and prostanoids—a nanotechnological approach. Prostaglandins,
leukotrienes, and essential fatty acids. 2005; 72(2):105–13. Epub 2005/01/01.
47. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free radical
biology & medicine. 2009; 47(4):344–56. Epub 2009/05/30. https://doi.org/10.1016/j.freeradbiomed.
2009.05.018
PLOS ONE | https://doi.org/10.1371/journal.pone.0187189 November 2, 2017 17 / 17
